Systematic review / meta-analysis / 2014
Glucosamine's effect on osteoarthritis pain varied substantially by brand and study risk of bias.
A systematic review and stratified meta-analysis of 25 randomized placebo-controlled trials with 3,458 patients assessed glucosamine for osteoarthritis pain. Overall, glucosamine moderately reduced pain (SMD -0.51 [95% CI -0.72, -0.30]) with high inconsistency (I2 = 88%). Brand explained 41% of heterogeneity (P = 0.00032): 12 trials using Rottapharm/Madaus showed significant pain reduction (SMD -1.07 [95% CI -1.47, -0.67]), but a sensitivity analysis of 3 low risk-of-bias trials of this brand showed only a small effect (SMD -0.27 [95% CI -0.43, -0.12]). Thirteen trials using non-Rottapharm/Madaus products failed to show pain reduction (SMD -0.11 [95% CI -0.46, 0.24]).
- Study type
- Stratified meta-analysis of randomized placebo-controlled trials
- Who was studied
- 3,458 osteoarthritis patients across 25 trials
- What was measured
- Reduction of pain (standardized mean difference)
THE PAPER
Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials.
Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Arthritis Care Res (Hoboken), 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.